Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Gray

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Frontiers in Medicine|May 15, 2026
rAAV9 vector biodistribution in nonhuman primate brain and spinal cord following lumbar intrathecal infusionEmdadul Haque, Nino Devidze, Suku Nagendran, et al.
Molecular Therapy. Nucleic Acids|February 7, 2013
Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of OsteoarthritisLaurie R Goodrich, Jennifer N Phillips, C Wayne McIlwraith, et al.
Experimental Eye Research|April 30, 2021
Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten diseaseSamantha J Murray, Katharina N Russell, Tracy R Melzer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2010
Transient demyelination increases the efficiency of retrograde AAV transductionEdmund R Hollis, Pouya Jamshidi, Ariana O Lorenzana, et al.
Molecular Therapy. Methods & Clinical Development|March 12, 2016
Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivoMichael B Tropak, Sayuri Yonekawa, Subha Karumuthil-Melethil, et al.
Communications Medicine|January 27, 2025
Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiencyMaximiliano Presa, Rachel M Bailey, Somdatta Ray, et al.
Molecular Therapy. Methods & Clinical Development|January 11, 2024
Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage studyAlex E Ryckman, Natalie M Deschenes, Brianna M Quinville, et al.
Frontiers in Cellular Neuroscience|March 26, 2025
Riboflavin transporter deficiency: <i>AAV9-SLC52A2</i> gene therapy as a new therapeutic strategyCecilia Mei, Valentina Magliocca, Xin Chen, et al.
JCI Insight|June 8, 2023
CNS-dominant human FMRP isoform rescues seizures, fear, and sleep abnormalities in Fmr1-KO miceHayes Wong, Alexander Wm Hooper, Hye Ri Kang, et al.
Human Gene Therapy|March 30, 2011
Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene deliveryBrooke R Snyder, Steven J Gray, Eric T Quach, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Frontiers in Medicine|May 15, 2026
rAAV9 vector biodistribution in nonhuman primate brain and spinal cord following lumbar intrathecal infusionEmdadul Haque, Nino Devidze, Suku Nagendran, et al.
Molecular Therapy. Nucleic Acids|February 7, 2013
Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of OsteoarthritisLaurie R Goodrich, Jennifer N Phillips, C Wayne McIlwraith, et al.
Experimental Eye Research|April 30, 2021
Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten diseaseSamantha J Murray, Katharina N Russell, Tracy R Melzer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 27, 2010
Transient demyelination increases the efficiency of retrograde AAV transductionEdmund R Hollis, Pouya Jamshidi, Ariana O Lorenzana, et al.
Molecular Therapy. Methods & Clinical Development|March 12, 2016
Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivoMichael B Tropak, Sayuri Yonekawa, Subha Karumuthil-Melethil, et al.
Communications Medicine|January 27, 2025
Preclinical use of a clinically-relevant scAAV9/SUMF1 vector for the treatment of multiple sulfatase deficiencyMaximiliano Presa, Rachel M Bailey, Somdatta Ray, et al.
Molecular Therapy. Methods & Clinical Development|January 11, 2024
Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage studyAlex E Ryckman, Natalie M Deschenes, Brianna M Quinville, et al.
Frontiers in Cellular Neuroscience|March 26, 2025
Riboflavin transporter deficiency: <i>AAV9-SLC52A2</i> gene therapy as a new therapeutic strategyCecilia Mei, Valentina Magliocca, Xin Chen, et al.
JCI Insight|June 8, 2023
CNS-dominant human FMRP isoform rescues seizures, fear, and sleep abnormalities in Fmr1-KO miceHayes Wong, Alexander Wm Hooper, Hye Ri Kang, et al.
Human Gene Therapy|March 30, 2011
Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene deliveryBrooke R Snyder, Steven J Gray, Eric T Quach, et al.
Pageof 11